Aquestive Therapeutics, Inc. AQST Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.45M+65.7% | $13.02M+9.7% | $12.81M-5.4% | $10M-50.2% | $8.72M-27.7% | ||
| $3.47M-5.0% | $5.84M+29.1% | $4.51M+1.6% | $4.56M+0.8% | $3.65M-16.8% | ||
| $10.98M+117% | $7.18M-2.3% | $8.3M-8.8% | $5.44M-65.1% | $5.07M-33.9% | ||
| 76%+17.9pp | 55.2%-6.8pp | 64.8%-2.4pp | 54.4%-23.1pp | 58.1%-5.5pp | ||
| $4.2M-21.6% | $3.2M-35.0% | $4.53M-14.0% | $4.11M-1.4% | $5.36M-9.6% | ||
| $10.98M-42.4% | $32.82M+105% | $15.25M+25.8% | $12.71M+11.9% | $19.07M+78.4% | ||
| $18.65M-33.6% | $41.85M+64.5% | $24.29M+11.2% | $21.37M+6.6% | $28.09M+33.7% | ||
| -$4.2M+78.3% | -$28.84M-112% | -$11.48M-38.5% | -$11.37M-20,769% | -$19.37M-116% | ||
| -29.1%+193pp | -221.6%-107pp | -89.6%-28.4pp | -113.6%-114pp | -222.1%-148pp | ||
| $2.9M+4.3% | $2.78M0.0% | $2.78M0.0% | $2.78M+0.1% | $2.78M-0.1% | ||
| -$8.06M+64.9% | -$31.86M-86.7% | -$15.45M-34.2% | -$13.55M-394% | -$22.93M-78.7% | ||
| -$8.06M+64.9% | -$31.86M-86.8% | -$15.45M-34.2% | -$13.55M-394% | -$22.93M-78.7% | ||
| -55.8%+207pp | -244.8%-101pp | -120.6%-35.6pp | -135.4%-122pp | -263%-157pp | ||
| -$0.07+70.8% | -$0.27-42.1% | -$0.14-7.7% | -$0.14-367% | -$0.24-41.2% | ||
| -$0.07+70.8% | -$0.27-42.1% | -$0.14-7.7% | -$0.14-367% | -$0.24-41.2% | ||
| 122.6M+28.4% | 106.9M+23.3% | 110.6M+21.4% | 99.3M+9.3% | 95.5M+29.7% | ||
| 122.6M+28.4% | 106.9M+23.3% | 110.6M+21.4% | 99.3M+9.3% | 95.5M+29.7% | ||
| $973K-32.3% | $1.43M+3.5% | $1.43M+5.4% | $1.43M+5.6% | $1.44M+5.8% | ||
| $83K-88.4% | $1.25M+70.6% | $306K-68.7% | $2.1M+50.3% | $713K+117% | ||
| $60K+1.7% | $62K+1.6% | $61K+3.4% | $61K+5.2% | $59K+1.7% | ||
| -$8.06M+64.9% | -$31.86M-86.8% | -$15.45M-34.2% | -$13.55M-394% | -$22.93M-78.7% | ||
| $14.45M+65.7% | $13.02M+9.7% | $12.81M-5.4% | $10M-50.2% | $8.72M-27.7% | ||
| -$4.2M+78.3% | -$28.84M-112% | -$11.48M-38.5% | -$11.37M-20,769% | -$19.37M-116% | ||
| -$4.09M+78.7% | -$28.71M-114% | -$11.34M-39.5% | -$11.23M-4,418% | -$19.23M-120% | ||
| -$4.09M+78.7% | -$28.71M-114% | -$11.34M-39.5% | -$11.23M-4,418% | -$19.23M-120% | ||
| -28.3%+192pp | -220.6%-107pp | -88.5%-28.5pp | -112.2%-114pp | -220.5%-148pp | ||
| -$4.2M+78.3% | -$28.84M-112% | -$11.48M-38.5% | -$11.37M-20,769% | -$19.37M-116% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aquestive Therapeutics, Inc.'s revenue?
- Aquestive Therapeutics, Inc. (AQST) generated $50.3M in revenue over the trailing twelve months, down 7.3% year over year.
- Is Aquestive Therapeutics, Inc. profitable?
- Aquestive Therapeutics, Inc. is not currently profitable: it reported a net loss of $68.9M over the trailing twelve months, a -137.1% net margin.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Gross margin is 63.5% and operating margin is -111.2%, with a -137.1% net margin.
- What is Aquestive Therapeutics, Inc.'s earnings per share?
- Aquestive Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.62.
- Where does Aquestive Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
